Argenx
ARGX
#476
Rank
HK$408.43 B
Marketcap
HK$6,536
Share price
-1.72%
Change (1 day)
41.39%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): HK$68.96

According to Argenx 's latest financial reports the company's current EPS (TTM) is HK$69.47. In 2024 the company made an earnings per share (EPS) of HK$109.02 an increase over its 2023 EPS that were of -HK$40.41.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$68.96-36.75%
2024HK$109.02-369.77%
2023-HK$40.41-60.46%
2022-HK$102.2163.33%
2021-HK$62.58-40.37%
2020-HK$104.95183.47%
2019-HK$37.02123.09%
2018-HK$16.6054.93%
2017-HK$10.7114.07%
2016-HK$9.3913.05%
2015-HK$8.31-36.34%
2014-HK$13.05209.04%
2013-HK$4.22-33.99%
2012-HK$6.40185.59%
2011-HK$2.24